Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Colorcon
Baxter
Boehringer Ingelheim
Mallinckrodt

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Danirixin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Danirixin: Sponsors, patents, clinical trial progress

Danirixin is an investigational drug.

There have been 10 clinical trials for Danirixin. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, and Chronic Disease. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

There are two US patents protecting this investigational drug and fifty-five international patents.

Recent Clinical Trials for Danirixin
TitleSponsorPhase
GSK1325756 Relative Bioavailability Study in Healthy Elderly SubjectsGlaxoSmithKlinePhase 1
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)GlaxoSmithKlinePhase 2
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)GlaxoSmithKlinePhase 2

See all Danirixin clinical trials

Clinical Trial Summary for Danirixin

Top disease conditions for Danirixin
Top clinical trial sponsors for Danirixin

See all Danirixin clinical trials

US Patents for Danirixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Danirixin   See Pricing IL-8 receptor antagonists GlaxoSmithKline, LLC (Philadelphia, PA)   See Pricing
Danirixin   See Pricing Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2- -methylphenyl)urea GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Danirixin

Drugname Country Document Number Estimated Expiration Related US Patent
Danirixin Argentina 060562 2026-04-21   See Pricing
Danirixin Australia 2007240365 2026-04-21   See Pricing
Danirixin Brazil PI0710232 2026-04-21   See Pricing
Danirixin Canada 2650009 2026-04-21   See Pricing
Danirixin Chile 2007001142 2026-04-21   See Pricing
Danirixin China 101472477 2026-04-21   See Pricing
Danirixin Costa Rica 10391 2026-04-21   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Mallinckrodt
Boehringer Ingelheim
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.